Amgen Profit Drops 49% in 3rd Quarter
- Share via
Amgen said it earned $177,000 in the third quarter that ended Dec. 31, down 49% from a year earlier.
The decline in the Thousand Oaks biotechnology company’s profit came despite revenue for the quarter rising 57% to $21.3 million, money that came mostly from corporate partners to pay for research by Amgen. Amgen is awaiting Food and Drug Administration approval of its first major product, an anti-anemia drug called erythropoietin.
For the nine months, Amgen’s profit fell 35% to $802,000 as revenue climbed 61% to $62.3 million.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
